Erdoğan Selçuk ŞEBER, Eyyüp ÇAVDAR, Yakup İRİAĞAÇ, Kubilay KARABOYUN, Okan AVCI

Neoadjuvan Kemoterapi Alan Meme Kanseri Hastalarında COVID-19 Pandemisinin Tanı ve Tedavi Sürecine Etkileri

Amaç: Bu çalışmamızda neoadjuvan kemoterapi alan meme kanseri hastalarında pandeminin tanı-tedavi sürecine etkisini araştırdık. Gereç ve Yöntem: Koronavirüs hastalığı-2019 (COVID-19) pandemisi dönemindeki bir yıl ile pandemi öncesindeki 1 yılda neoadjuvan kemoterapi alan hastaların klinikopatolojik özellikleri ile tanıdan operasyona kadar olan aşamaların süreleri karşılaştırıldı. Toplam 92 hasta retrospektif olarak analiz edildi. Bulgular: Pandemi ve pandemi öncesi (prepandemik) dönemdeki hastaların klinikopatolojik özellikleri benzer bulundu. Pandemi dönemindeki hasta sayısı 26 (%28,3) iken pandemi öncesi dönemde 66 (%71,7) idi. Tanı-tedavi sürelerinden patoloji raporlanma süresi, kemoterapi uygulanma süresi ve preoperatif hazırlık dönemi ve total süre iki dönem arasında benzerdi (sırasıyla; p=0,305, p=0,171, p=0,104, p=0,061). Manyetik rezonans raporlanma süresi pandemi döneminde daha kısa saptandı (p=0,005). Sonuç: Neoadjuvan kemoterapi alan hastalarda meme kanserinin tanı ve tedavi süreleri pandemi döneminde, pandemi öncesi dönemle benzerdir. Yine de COVID-19 enfeksiyon riski düşünülerek hasta özelinde karar verilmelidir.

Effects of COVID-19 Pandemic on Diagnosis-treatment Process in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Aim: In this study, we investigated the effect of pandemic on the diagnosis-treatment process in breast cancer patients receiving neoadjuvant chemotherapy. Materials and Methods: The clinicopathological characteristics of the total patients who received neoadjuvant chemotherapy for one year during the Coronavirus disease-2019 (COVID-19) pandemic period and one year before the pandemic were compared. A total of 92 patients were analyzed retrospectively. Results: The clinicopathological features in the pandemic and prepandemic periods were found to be similar. While the number of patients was 26 (28.3%) during the pandemic period, it was 66 (71.7%) in the prepandemic period. Pathology reporting time, chemotherapy administration time, preoperative preparation time and overall time from diagnosis to treatment were similar (p=0.305, p=0.171, p=0.104, p=0.061, respectively). Magnetic resonance reporting time was shorter during the pandemic period (p=0.005). Conclusion: The diagnosis and treatment times of breast cancer in patients receiving neoadjuvant chemotherapy in the pandemic period are similar to those in the pre-pandemic period. Nevertheless, decision should be made on a patient-specific basis considering COVID-19 infection risk.

PDF

___

1. WHO. Director-General’s opening remarks at the media briefing on COVID-19. Erişim tarihi: 11 Mart 2020. Erişim adresi: https://www.who. int/director-general/speeches/detail/who-director-general-s-opening- remarks-at-the-media-briefing-on-covid-19---11-march-2020
2. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2021. Erişim adresi: https://web.archive.org/web/20210101171129/https://covid19.who.int
3. Gostin LO, Wiley LF. Governmental Public Health Powers During the COVID-19 Pandemic: Stay-at-home Orders, Business Closures, and Travel Restrictions. JAMA. 2020;323:2137-8.
4. Yezli S, Khan A. COVID-19 social distancing in the Kingdom of Saudi Arabia: Bold measures in the face of political, economic, social and religious challenges. Travel Med Infect Dis. 2020;37:101692.
5. T.C. Sağlık Bakanlığı. COVID-19 Bilgilendirme Platformu. 2021. Erişim adresi: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html
6. T.C. İçişleri Bakanlığı. 65 Yaş ve Üstü ile Kronik Rahatsızlığı Olanlara Sokağa Çıkma Yasağı Genelgesi. 2021. Erişim adresi: https://www.icisleri.gov. tr/65-yas-ve-ustu-ile-kronik-rahatsizligi-olanlara-sokaga-cikma-yasagi- genelgesi
7. Chabner BA. Taking the Longer View of COVID-19. Oncologist. 2020;25:455- 7.
8. Manoj Gowda S, Kabeer KK, Jafferbhoy S, Marla S, Soumian S, Misra V, et al. Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian J Surg. 2020:1-8.
9. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335-7.
10. Ismaili N. COVID-19 Recommendations for Patients with Cancer: The post- COVID-19 Era. SN Compr Clin Med. 2020:1-6.
11. Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43-50.
12. Society of Surgical Oncology. Resource for Management Options of Breast Cancer During COVID-19. 2020. Erişim adresi: https://www.surgonc.org/wp- content/uploads/2020/03/Breast-Resource-during-COVID-19-3.23.20.pdf
13. Colombo I, Zaccarelli E, Del Grande M, Tomao F, Multinu F, Betella I, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. ESMO Open. 2020;5(Suppl 3):e000827.
14. Sezer A, Cicin İ, Karadeniz Çakmak G, Özkan Gürdal S, Başaran G, Oyan B, et al. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak. Turk J Surg. 2020;36:147-63.
15. Daraï E, Mathelin C, Gligorov J. Breast Cancer Management during the COVID 19 Pandemic: French Guidelines. Eur J Breast Health. 2020;16:160-1. 16. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
17. Oseran AS, Nash D, Kim C, Moisuk S, Lai PY, Pyhtila J, et al. Changes in hospital admissions for urgent conditions during COVID-19 pandemic. Am J Manag Care. 2020;26:327-8.
18. Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66:504-11.
19. Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020;88:901-7.
20. Karacin C, Bilgetekin I, B Basal F, Oksuzoglu OB. How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer. Future Oncol. 2020;16:2283-93.
21. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al. Impact of the COVID-19 Pandemic on Emergency Department Visits - United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:699-704.
22. Gülşen İ. Covid-19 pandemisinin kronik viral hepatit hizmetleri üzerinde etkisi. Kesit Akad Derg. 2020;6:685-93.
23. Roberton T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. Lancet Glob Health. 2020;8:e901-e8.
24. Sheng JY, Santa-Maria CA, Mangini N, Norman H, Couzi R, Nunes R, et al. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract. 2020;16:665-74.
25. Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, et al. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol. 2016;23:1515-21.
26. Müller C, Juhasz-Böss I, Schmidt G, Jungmann P, Solomayer EF, Breitbach GP, et al. Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients. Arch Gynecol Obstet. 2020;301:1055-9.
27. Krishnamurthy A. Advances in surgery in 2020: The impact of the COVID-19 pandemic on cancer surgeries and cancer care - a brief overview. Indian J Cancer. 2021;58:38-40.